1.89 USD
▲+0.04+12.50%
2026-08-03
市值
$2.30M
市盈率
—
EPS
-63.37
股息率
—
52 周区间
1.48 – 117.13
成交量
275.52K
Beta
1.30
目标价
—
52W 低 1.4852W 高 117.13
价格走势
公司简介
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as Ne...